Economic Comparison Between the Use of Ultrasonic Scissors and Diathermy for Axillary Clearance in Breast Cancer Patients
Breast surgery plays an important role in the treatment of breast cancer. This study investigates if the use of Harmonic Focus has advantages than the use of conventional diathermy in axillary clearance due to metastatic breast cancer.
NCT05901064 — Seroma
Status: Recruiting
http://inclinicaltrials.com/seroma/NCT05901064/
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients: A Multi-center, Prospective, Observational Study
The goal of this clinical trial is to learn about the mutation spectrum of homologous recombination repair pathway genes and its instructive significance in the treatment of Chinese breast cancer patients.
NCT05901025 — Breast Cancer
Status: Not yet recruiting
http://inclinicaltrials.com/breast-cancer/NCT05901025/
Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
NCT05900895 — Metastatic Breast Cancer
Status: Not yet recruiting
http://inclinicaltrials.com/metastatic-breast-cancer/NCT05900895/
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main questions it aims to answer are: - is T-DXd more effective than standard preoperative treatment? - are there markers in the tumor or blood of patients with HER2-positive breast cancer that can help us predict response to treatment? Participants will be divided into two groups, where one group will be treated with three courses of T-DXd and the other group will be treated with three courses standard of care treatment. Thereafter, further treatment will be decided by the tumor's molecular subtype.
NCT05900206 — Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/breast-cancer/NCT05900206/
Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer: Non-randomized Phase II, Prospective Single Arm Study Clinical Trial
The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy. The main questions it aims to answer are: - 5-year disease-free survival - 5-year overall survival - 5-year locoregional recurrence - Adverse events after radiation therapy - Quality of life Participants will be assessed by multi-dimensional methods before and after radiotherapy: - Disease status evaluation including physical and radiological examination - Quality of life assessment with questionnaires (BREAST-Q) - Adverse event assessment according to CTCAE version 5.0
NCT05896865 — Breast Cancer Stage III
Status: Recruiting
http://inclinicaltrials.com/breast-cancer-stage-iii/NCT05896865/
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery. The main questions it aims to answer are: - 7-year ipsilateral breast tumor recurrence - 7-year disease-free survival - 7-year locoregional recurrence - 7-year overall survival - Adverse events of radiation therapy Participants will be assessed by multi-dimensional methods after radiation therapy: - Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination - Assessment for the adverse events according to CTCAE version 5.0
NCT05893966 — Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/breast-cancer/NCT05893966/
Short-course Trastuzumab, Pertuzumab Combined With Taxanes in the Adjuvant Treatment of Early Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: an Open-label, Single-arm Study
The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.
NCT05891561 — Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/breast-cancer/NCT05891561/
The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema: A Pragmatic, Randomized, Multicenter Superiority Trial
The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)
NCT05890677 — Lymphedema, Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/lymphedema-breast-cancer/NCT05890677/
Assessment of the Diagnostic and Theranostic Potential of Ga Bombesin PET/CT (NeoB) Imaging for Staging of ER/PR + HER2- Breast Cancer Patients With Metastatic Disease: Comparison to Conventional Imaging
This phase IIb pilot study will enrol 20 patients (women) presenting with metastatic breast cancer (ER/PR + HER2- on histology) who require imaging for staging or re-staging of their disease.
NCT05889728 — Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/breast-cancer/NCT05889728/
[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
NCT05889390 — HER2-negative Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/her2-negative-breast-cancer/NCT05889390/